1. In Vivo
  2. >>Market Intelligence

US Adalimumab Outlook Brightens At Mid-Point Of 2024

PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars

 
• By Dave Wallace

The latest figures on uptake of rivals to AbbVie's Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator after an initially slow start in 2023.

Chart showing trending up in 2024
Uptake is beginning to ramp up for US adalimumab biosimilars in 2024 • Source: Shutterstock

Ever since biosimilar competition to AbbVie Inc.'s Humira (adalimumab) began to hit the US market in early 2023, all eyes have been on the uptake of off-patent rivals, given that the product represented the largest loss-of-exclusivity opportunity in history – valued at roughly $17bn in terms of brand sales.

Despite the excitement around the launches – which saw Amgen compete with the first US biosimilar in January 2023, followed...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Intelligence

More from In Vivo

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.